Cumberland Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Cumberland Pharmaceuticals shares (CPIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cumberland Pharmaceuticals employs 90 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.48 |
|---|---|
| 52-week range | $2.20 - $7.51 |
| 50-day moving average | $4.00 |
| 200-day moving average | $3.18 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.48 from 2022-01-25
| 1 week (2022-01-19) | -4.40% |
|---|---|
| 1 month (2021-12-23) | -32.03% |
| 3 months (2021-10-26) | 33.33% |
| 6 months (2021-07-26) | 6.10% |
| 1 year (2021-01-26) | 7.08% |
|---|---|
| 2 years (2020-01-24) | -30.40% |
| 3 years (2019-01-25) | 5.65 |
| 5 years (2017-01-26) | 6.25 |
Valuing Cumberland Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cumberland Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cumberland Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $154,811.
The EBITDA is a measure of a Cumberland Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $37.9 million |
|---|---|
| Gross profit TTM | $28.8 million |
| Return on assets TTM | -3.45% |
| Return on equity TTM | -6.34% |
| Profit margin | -1.43% |
| Book value | $3.15 |
| Market capitalisation | $46.8 million |
TTM: trailing 12 months
We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.
Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 5 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.
Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $2.2 up to $7.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.0096. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.